Basics Novavax, Inc. Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. IPO Date: December 13, 1995 Sector: Healthcare Industry: Biotech Market Cap: $1.4B Activated in VL: True Average Daily Range Avg Daily Range: $0.82 | 3.61% Avg Daily Range (30 D): $0.21 | 2.46% Avg Daily Range (90 D): $0.20 | 2.51% Institutional Daily Volume Avg Daily Volume: 3.99M Avg Daily Volume (30 D): 4.28M Avg Daily Volume (90 D): 5.41M Trade Size Avg Trade Size (Sh.): 196 Avg Trade Size (Sh.) (30 D): 148 Avg Trade Size (Sh.) (90 D): 164 Institutional Trades Total Inst.Trades: 8,717 Avg Inst. Trade: $3.52M Avg Inst. Trade (30 D): $2.12M Avg Inst. Trade (90 D): $1.85M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $6.69M Avg Closing Trade (30 D): $2.5M Avg Closing Trade (90 D): $2.58M Avg Closing Volume: 226.43K     News Sep 26, 2025 @ 4:08 AM Robert F. Kennedy Jr. Faces Impeachment Push From ... Source: Vishaal Sanjay Sep 10, 2025 @ 5:21 PM FDA Moves To Publicize Data On Pregnant Women's Co... Source: Vandana Singh Aug 12, 2025 @ 5:41 PM CDC Shooting Linked To Suspect's COVID-19 Vaccine ... Source: Vandana Singh Jun 30, 2025 @ 1:51 PM Moderna's mRNA Flu Vaccine Outperforms Standard Sh... Source: Vandana Singh Jun 29, 2025 @ 6:08 PM Vaccine Adjuvants Market to Reach USD 5.43 Billion... Source: Sns Insider Financials   TTM Q2 2025 Q1 2025 Basic EPS $2.59 $.66 $3.22 Diluted EPS $2.27 $.62 $2.93 Revenue $ 1.08B $ 239.24M $ 666.66M Gross Profit $ 951.99M $ 223.92M $ 652.54M Net Income / Loss $ 422.82M $ 106.51M $ 518.65M Operating Income / Loss $ 351.49M $ 101.07M $ 515.51M Cost of Revenue $ 126.73M $ 15.33M $ 14.12M Net Cash Flow $ -426.58M $ -9.5M $ -266.81M PE Ratio 3.67     Splits May 10, 2019:   1:20